Clear Street’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Clear Street’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43K	Buy	711,917 +86,482	+14%	+$9.16K	﹤0.01%	771
2025 Q4	$117K	Sell	625,435 -33,658	-5%	-$6.53K	﹤0.01%	488
2025 Q3	$143K	Sell	659,093 -12,994	-2%	-$2.42K	﹤0.01%	373
2025 Q2	$80.8K	Buy	672,087 +121,911	+22%	+$15.7K	﹤0.01%	286
2025 Q1	$71.5K	Buy	+550,176	New	+$77.2K	﹤0.01%	155

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Clear Street's DMAAR Position: Q1 2026 in Review

Clear Street increased its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 14% in Q1 2026, buying an estimated $9.16K and bringing the position to 711,917 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #771.

Clear Street first reported a position in DMAAR in Q1 2025 and has held it in 5 quarters since. The position peaked at $143K in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

Clear Street held 711,917 shares of Drugs Made In America Acquisition Corp Rights worth $43K as of Q1 2026.
Clear Street bought 86,482 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $9.16K.
Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Clear Street's portfolio in Q1 2026, its #771 holding.
Clear Street first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 5 quarters since.
Clear Street's Drugs Made In America Acquisition Corp Rights position peaked at $143K in Q3 2025.
35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Clear Street's 13F filing for Q1 2026, filed 15 May 2026.